Lisa Astor

Improvements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.

Results from the real-world analysis of the phase 2 HER2CLIMB trial showed a good safety profile with the tucatinib triplet regimen in patients with HER2-positive metastatic breast cancer.

Circulating tumor DNA levels could be a potential prognostic tool for predicting outcomes in diffuse large B-cell lymphoma.

Progression-free survival and overall survival were enhanced with the use of bevacizumab plus first-line chemotherapy in ovarian clear cell carcinoma.

Superior efficacy was observed when patients with RAS wild–type metastatic colorectal cancer were treated with panitumumab plus chemotherapy vs bevacizumab in the first-line setting.

Ribociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer following progression on a CDK4/6 inhibitor bests matched placebo.

Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.

Adding niraparib to abiraterone acetate and prednisone improved efficacy and yielded tolerable safety for patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.

The safety and efficacy of NG-641 plus nivolumab will be assessed as part of the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumor.

Findings from the OCTOPUS Consortium of trial data indicated that weight-based chemotherapy dosing may improve outcomes for obese patients with colorectal cancer.

Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.

Some patients who progressed on osimertinib had a response to therapy with amivantamab and lazertinib, and these were seen regardless of known resistance mechanisms to EGFR inhibitors.

Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.

Results of prospective, open-label trial of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer continued to demonstrate efficacy of the PARP inhibitor in this setting.

An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.

Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.

Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.

Compared against sunitinib, nivolumab plus cabozantinib induced better outcomes in patients with advanced renal cell carcinoma and these results were seen in patients with and without sarcomatoid features.

Trastuzumab deruxtecan treatment demonstrated strong antitumor activity for patients with HER2-overexpressing NSCLC, regardless of HER2 expression levels, according to interim findings from the phase 2 DESTINY Lung-01 trial.

When compared with standard capecitabine and bevacizumab therapy, patients with unresectable metastatic colorectal cancer saw an increase in overall and progression-free survival.

Patient's surgical risk for potentially resectable advanced thoracic esophageal cancer is not negatively impacted by neoadjuvant chemotherapy, study finds.

Final data from a phase 2 trial suggested that the administration of trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

TNB-383B was well tolerated and researchers saw significant responses when it was administered at a higher dose level for heavily pretreated patients with relapsed/refractory multiple myeloma.

Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.

A phase 1 trial showed that treatment with neoadjuvant nivolumab was tolerable in patients with nonmetastatic high-risk clear cell renal cell carcinoma.

Findings from the phase 2 FLIPPER trial indicated that frontline fulvestrant (Faslodex) in combination with palbociclib (Ibrance) demonstrated an improvement in PFS at 1 year in patients with endocrine-sensitive HR-positive, HER2-negative metastatic breast cancer.